ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

ResMed dominates healthcare devices with innovation, recurring revenues, and market leadership. See why we believe RMD stock ...

Morgans senior healthcare analyst Scott Power says healthcare stocks have had a strong start to the latest reporting season.